Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company Drug

Rakuten Medical Taiwan Administers First Dose of ASP-1929 in Phase II Trial

Fineline Cube Jun 22, 2022

Rakuten Medical Taiwan Inc. announced the administration of its photo-immunotherapy ASP-1929 to the first patient...

Company Drug

BeiGene’s Tislelizumab Accepted for Review in Gastric Cancer Treatment

Fineline Cube Jun 22, 2022

BeiGene (NASDAQ: BGNE) announced that a supplementary Biologic License Application (sBLA) for its programmed death-1...

Company Drug

Zelgen’s Jakitinib Phase III Study Meets Primary Endpoint for Myelofibrosis

Fineline Cube Jun 22, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that its Phase III clinical study (ZGJAK016)...

Company Deals

Nanjing CRO Caremo Secures RMB 150 Million in Series A Round

Fineline Cube Jun 22, 2022

Nanjing-based Contract Research Organization (CRO) Caremo has reportedly secured RMB 150 million (USD 22.3 million)...

Company Drug

Lee’s Pharmaceutical Wins NMPA Approval for ALS Drug Teglutik

Fineline Cube Jun 22, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has announced receiving market approval from the National...

Company Deals Hospital

Winsan Medical Acquires 52% Stake in Goodfeel Dental Clinic for RMB 156 Million

Fineline Cube Jun 22, 2022

China-based Winsan (Chengdu) Medical Science and Technology Co., Ltd (SHA: 600767) is set to acquire...

Company Drug

InnoCare Pharma’s ICP-189 First Dosed in China SHP2 Inhibitor Trial

Fineline Cube Jun 22, 2022

Beijing InnoCare Pharma (HKG: 9969) has announced the first patient dosing in a clinical study...

Company Deals

China NT Pharma Group Inks Licensing Deal for Orticumab in Asia

Fineline Cube Jun 22, 2022

China-based China NT Pharma Group Company Ltd (HKG: 1011) has announced a licensing agreement with...

Company Deals

Mega Genomics Limited Makes Hong Kong IPO Debut at HKD 18 Per Share

Fineline Cube Jun 22, 2022

China-based gene testing platform company Mega Genomics Limited has successfully completed an initial public offering...

Company Medical Device

Venus Medtech’s VenusP-Valve Used Compassionately in US for Pulmonary Regurgitation

Fineline Cube Jun 22, 2022

Venus Medtech (Hangzhou) Inc. (HKG: 2500) announced the first compassionate use of its VenusP-Valve, a...

Company Drug

Merck KGaA’s Erbitux Approved in China for Head and Neck Cancer Treatment

Fineline Cube Jun 22, 2022

Germany-based pharmaceutical firm Merck KGaA announced that China’s National Medical Products Administration (NMPA) has issued...

Company Drug

CSPC’s JMT103 Accepted for Review in China, Targets RANKL-Related Deficiencies

Fineline Cube Jun 22, 2022

The Center for Drug Evaluation (CDE) website indicates that a market filing by China-based CSPC...

Company Medical Device

Grand Pharma Launches SIR-Spheres for Liver Cancer Treatment in China

Fineline Cube Jun 22, 2022

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the official launch of its SIR-Spheres...

Policy / Regulatory R&D

Beijing Introduces White List System for Biomedical R&D Item Imports

Fineline Cube Jun 21, 2022

Beijing has announced the introduction of a ‘white list’ system to facilitate the import of...

Company Drug

Ocumension Therapeutics’ OT-401 Approved for Chronic Non-Infectious Uveitis in China

Fineline Cube Jun 21, 2022

China-based Ocumension Therapeutics (HKG: 1477) has received approval from the National Medical Products Administration (NMPA)...

Company

AstraZeneca Expands in China with Qingdao Partnership and Manufacturing Base

Fineline Cube Jun 21, 2022

UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is significantly expanding its presence in China through a...

Company Drug

CStone Pharmaceuticals’ Ayvakit Included in Taiwan’s National Health Insurance

Fineline Cube Jun 21, 2022

China-based CStone Pharmaceuticals (HKG: 2616) announced that its Ayvakit (avapritinib), a tyrosine kinase inhibitor for...

Company Deals

Eureka Biotechnology Secures RMB 100 Million for Cell and Gene Therapy Solutions

Fineline Cube Jun 21, 2022

Shenzhen-based Eureka Biotechnology, a company specializing in comprehensive solutions for the cell and gene therapy...

Company Deals

Therorna Secures Over RMB 280 Million in Series A Round to Accelerate circRNA Tech Development

Fineline Cube Jun 21, 2022

China-based Therorna Inc., a biotech company specializing in cutting-edge circular RNA (circRNA) technology for next-generation...

Company Medical Device

Qingdao HuaRen Pharmaceutical Gains CE Marks for Monkeypox and COVID-19 Detection Kits

Fineline Cube Jun 21, 2022

China-based Qingdao HuaRen Pharmaceutical Co., Ltd (SHE: 300110) has announced receiving CE marks in the...

Posts pagination

1 … 655 656 657 … 662

Recent updates

  • China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban
  • Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies
  • Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort
  • Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance
  • Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Company

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.